文献速递肾小球疾病慢性肾脏病

儿童IgA肾病的蛋白尿缓解与长期肾脏结局

Proteinuria remission and long-term kidney outcome in children with IgA nephropathy.
PubMed 文献 · Nephrol Dial Transplant · 2026-07-11

该多民族队列研究纳入709例活检时蛋白尿≥0.2 g/day/1.73m²的IgA肾病患儿,评估完全持续蛋白尿缓解(CSR)的发生率及其对长期eGFR下降的影响。结果显示CSR发生率为55.7%,且与4年和5年时eGFR下降的显著保护相关。

要点

  • 儿童IgA肾病中CSR发生率为55.7%。
  • 达到CSR与4年和5年eGFR下降显著保护相关。
  • 年轻、较高eGFR、无节段性硬化及RASB治疗与CSR显著相关。

核心结论

  • 儿童IgA肾病患者达到完全持续蛋白尿缓解与更好的eGFR结局相关。

主要发现

  • CSR发生于395例(55.7%),中位观察时间0.7年(0.4-1.3年),47.3%的病例维持至随访结束。
  • 达到CSR的儿童在4年和5年时eGFR下降显著受保护(p=0.026和p=0.004)。
  • 多变量Cox模型显示年轻(p=0.009)、较高eGFR(p=0.002)、无节段性硬化(p<0.001)和RASB治疗(p<0.001)与CSR显著相关。
  • 包含种族的模型显示日本和中国种族效应强(均p<0.001),CSR与年龄、无S1(p<0.001)和无T1-2(p=0.016)及RASB和IS治疗(均p<0.01)显著相关。

关键数值与推荐

  • KDIGO和IPNA指南推荐儿童IgA肾病蛋白尿目标<0.2 g/day/1.73m²。

临床怎么用

  • 在儿童IgA肾病中,应关注蛋白尿缓解至<0.2 g/day/1.73m²以改善长期eGFR结局。

局限性

  • 观察性研究,CSR与结局的关联可能受未测量混杂影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: KDIGO and IPNA guidelines indicate a target of proteinuria < 0.2 g/day/1.73m2 in children with Immunoglobulin A nephropathy (IgAN). However, the value of proteinuria remission to this threshold was limited to small monoethnic cohorts, with unknown long-term kidney outcomes. METHODS: In a previously described multiethnic cohort of 1 298 children with IgAN, we selected those with proteinuria at kidney biopsy ≥ 0.2 g/day/1.73m² and analyzed the occurrence of complete and sustained proteinuria remission lasting > 90 days (CSR). Aim of the study was to investigate clinical and histological factors associated with CSR and the value on long-term eGFR decline. RESULTS: The study enrolled 709 children with different ethnicities (White, Chinese and Japanese). The median age at biopsy was 12.9 years, eGFR 95.7 ml/min/1.73m2 and proteinuria 1.2 g/day/1.73m2. MEST-C scoring detected M1 in 57% of the cases, E1 in 41.3%, S1 in 53.3%, T1-2 in 13.6% and C1-2 in 46.7%. CSR occurred in 395 children (55.7%) after time-averaged observation of 0.7 years (0.4-1.3 years) and was maintained throughout follow-up in 47.3% of the cases. In a sensitivity analysis, children who achieved CSR had significant protection from eGFR decline at 4 and 5-years (p = 0.026 and p = 0.004 respectively). During follow-up, 74.4% were treated with renin-angiotensin system blockers (RASB) and 67.4% with immunosuppressors (IS). In a Cox proportional multivariate model including time-dependent RASB and IS treatment, a significant association with CSR was detected for younger age (p = 0.009), higher eGFR (p = 0.002), absence of segmental sclerosis (p < 0.001) and RASB treatment (p < 0.001). The model including ethnicity showed a strong effect of Japanese and Chinese ethnicity (both p < 0.001) and a significant association of CSR with age, absence of S1 (p < 0.001) and T1-2 (p = 0.016) and RASB and IS treatment (both p < 0.01). CONCLUSIONS: The observational study showed that the achievement of CSR in children with IgAN was associated with better eGFR outcome.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Coppo R, Lucisano G, Peruzzi L, et al. Proteinuria remission and long-term kidney outcome in children with IgA nephropathy. Nephrol Dial Transplant. 2026. PMID: 42435039. doi:10.1093/ndt/gfag153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。